Mierxiati Abudurexiti

Dr. Mierxiati Abudurexiti

Fudan University Shanghai Cancer Center
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in The Prostate
Verified
Journal Article
Closed access
PDF file
MAMierxiati Abudurexiti
Mierxiati Abudurexiti
WZWenkai Zhu
Wenkai Zhu
YWYuchen Wang
Yuchen Wang
JWJun Wang
Jun Wang
WXWenhao Xu
Wenhao Xu
DYDing Ye
Ding Ye

28 January 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MAMierxiati Abudurexiti
Mierxiati Abudurexiti
JMJie Ma
Jie Ma
YLYao Li
Yao Li
CHChuanyi Hu
Chuanyi Hu
ZCZhikang Cai
Zhikang Cai
NJNing Jiang
Ning Jiang
Background: Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients. Methods: We collected clinicopathological data on bladder cancer patients ≤40 years old diagnosed between 1975 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database. Survival curves were generated using the Kaplan–Meier method, and the differences between groups were analyzed using the log-rank test. Univariate and multivariate Cox hazards regression analyses were performed to define hazard ratios (HRs) for cancer-specific survival (CSS). Results: There were statistical differences in race, histological type, cancer stage, tumor size, and surgery treatment groups between overall survival and CSS. Only tumor size and cancer stage were significant independent prognostic risk factors in younger bladder cancer patients for the prediction of CSS. Conclusion: Tumors greater than 30 mm in size and a more advanced stage of bladder cancer were indicative of a poor prognosis in bladder cancer patients ≤40 years old, and long-term follow-up is suggested.

11 March 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ZXZhang Xingming
Zhang Xingming
JWJianhua Wang
Jianhua Wang
MAMierxiati Abudurexiti
Mierxiati Abudurexiti
LDLeilei Du
Leilei Du
WZWei Zhang
Wei Zhang
WWWenfeng Wang
Wenfeng Wang
Background: Prostate cancer (PCa) is widely recognized as an immunologically “cold” tumor, characterized by a paucity of effector T cells and a limited response to immune checkpoint blockade therapy. Although the chemokine receptor CXCR6 has been identified as a marker of highly cytotoxic CD8 + T cells in other malignancies, its identity, regulatory mechanisms, and clinical significance in PCa remain poorly understood. Methods: We integrated newly generated and publicly available single-cell RNA sequencing data encompassing 90 651 cells from nine patients. Multicolor immunofluorescence and flow cytometry were performed on human PCa tissue specimens stratified by Gleason Score (GS). In parallel, syngeneic mouse models, bone marrow chimeras, and in vitro T-cell functional assays were employed to investigate the role, recruitment, and transcriptional regulation of CXCR6 + CD8 + T cells. Mechanistic investigations included bulk RNA-seq, chromatin immunoprecipitation-quantitative real-time PCR, pharmacologic modulation of FOXO1, and detailed analysis of the IL-10–STAT3 signaling pathway. Results: The CXCR6 + CD8 + T cells represent a transcriptionally distinct subset with high expression of cytotoxic markers ( GZMA , GZMB , and PRF1 ), and their frequency declines significantly with increasing GS. Intratumoral maintenance of these cells is sustained by CXCL16 secreted by IL1B + M1-like macrophages; the loss of this macrophage population in advanced tumors leads to depletion of CXCR6 + CD8 + T cells. Genetic ablation of CXCR6 or depletion of CD8 + T cells accelerates tumor growth, demonstrating the essential role of CXCR6 + CD8 + T cells in antitumor immunity. At the molecular level, the FOXO1–KLF2 axis transcriptionally represses CXCR6 expression, and IL-10-mediated activation of STAT3 upregulates FOXO1 and KLF2, thereby suppressing CXCR6 expression and impairing cytotoxic function. Pharmacologic inhibition of FOXO1 enhances the expansion of CXCR6 + CD8 + T cells and acts synergistically with anti-PD-1 therapy to inhibit tumor progression. Conclusions: The CXCR6 + CD8 + T cells are critical yet progressively diminished effectors in PCa. Their persistence within the tumor microenvironment depends on CXCL16 derived from M1-like macrophages and is counteracted by IL-10-driven FOXO1–KLF2 signaling. Targeting this regulatory axis—through inhibition of FOXO1 or IL-10, for example—represents a rational therapeutic strategy to restore CXCR6 + CD8 + T-cell-mediated immunity and enhance the efficacy of immunotherapy in PCa.

20 October 2019 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
MAMierxiati Abudurexiti
Mierxiati Abudurexiti
JWJun Wang
Jun Wang
NSNing Shao
Ning Shao
FWFang-Ning Wan
Fang-Ning Wan
WZWen-Kai Zhu
Wen-Kai Zhu
DYDing-Wei Ye
Ding-Wei Ye